National Pension Service Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

National Pension Service lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 11.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 265,123 shares of the life sciences company’s stock after selling 35,538 shares during the period. National Pension Service owned 0.17% of Illumina worth $35,428,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. WCM Investment Management LLC lifted its holdings in Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares in the last quarter. Primecap Management Co. CA lifted its holdings in Illumina by 3.6% in the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after purchasing an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of Illumina stock opened at $88.74 on Friday. The business has a 50-day moving average of $123.38 and a 200 day moving average of $132.96. Illumina, Inc. has a 12 month low of $87.50 and a 12 month high of $156.66. The stock has a market capitalization of $14.06 billion, a price-to-earnings ratio of -11.55, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the subject of a number of recent research reports. Robert W. Baird raised their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research note on Friday. Piper Sandler raised their target price on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group cut their target price on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $155.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.